Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.67 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.66 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.59 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29421606 | 1.00 | HTR2A (0.67) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL29594789 | 0.98 | HTR2A (0.68) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL124465 | 0.98 | HTR2A (0.68) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Bromide SCHEMBL15661932 | 0.97 | HTR2A (0.67) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Carbon Dioxide SCHEMBL14861874 | 0.93 | MTNR1A (0.65) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL8571210 | 0.91 | MTNR1A (0.69) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8021697 | 0.89 | MTNR1A (0.71) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8021722 | 0.88 | MTNR1A (0.69) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL3148273 | 0.88 | HTR2A (0.56) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL29032209 | 0.86 | HTR2A (0.65) | HTR2AMTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117776934-A | Preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2014072998-A1 | AN IMPROVED PROCESS FOR PREPARATION OF AGOMELATINE | CADILA HEALTHCARE LIMITED (IN) | 2014-05-15 | — | — | WO | claimed |
| CN-103113243-A | Synthetic method of 2-(7-methoxyl-1-naphthyl) ethylamine hydrochloride | SHANDONG FANGMING PHARM GROUP | 2013-05-22 | — | — | CN | claimed |
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| CN-117776934-A | Preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117776934-A | Preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4342879-A1 | VERY EFFICIENT PROCESS FOR THE PREPARATION OF AGOMELATINE | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2024-03-27 | — | — | EP | disclosed |
| CN-117720424-A | Continuous flow preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117304053-A | Purification method and application of agomelatine and/or intermediate thereof | 北京海美源医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117269354-A | Detection method of agomelatine related substances | 湖南省湘中制药有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
| CN-1145896-A | New alkoxyaryl compounds, their process of preparation and pharmaceutical compositions which contain them | ADIR (FR) | 1997-03-26 | — | — | CN | disclosed |
| US-5449689-A | Treating melatoninergic system disorders | ADIR ET COMPAGNIE (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5449690-A | Antihypercholesterol anf melatonin antagonist | ADIR ET COMPAGNIE (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5420158-A | Melatonin activity | ADIR ET COMPAGNIE (FR) | 1995-05-30 | — | — | US | disclosed |
| US-5389683-A | Useful in treating or preventing a disorder of the melatoninergic system | ADIR ET COMPAGNIE (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5385944-A | Naphthylethylureas and naphthylethylthioureas | ADIR ET COMPAGNIE (FR) | 1995-01-31 | — | — | US | disclosed |
| US-5318994-A | Treating melatoninergic disorders | ADIR ET COMPAGNIE (FR) | 1994-06-07 | — | — | US | disclosed |
| US-5225442-A | Melatoninergic disorders | ADIR ET COMPAGNIE (FR) | 1993-07-06 | — | — | US | disclosed |
| US-5194614-A | COMPOUNDS HAVING A NAPHTHALENE STRUCTURE | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | HTR2A 225/4885HTR2C 94/4885HTR2B 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.